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Abstract 
This paper reports the structure of the double mutant Asp251Gly/Gln307His (here 
called A2), generated by random mutagenesis, is able to produce 4’-
hydroxydiclofenac, 2-hydroxyibuprofen and 4-hydroxytolbutamide from diclofenac, 
ibuprofen and tolbutamide, respectively. Here, we report the crystal structure of the 
heme domain of the mutant in the substrate-free form and in complex with the 
substrate N-palmitoylglycine, together with its impact on thermal stability, reduction 
potential and electron transfer.  
The substrate-free structure adopts a conformation more similar to the closed one 
found in the substrate-bound wild type enzyme, but with a higher degree of disorder 
in the region of the G-helix and F-G loop, part of the substrate access channel. This 
is due to the mutation Asp251Gly that breaks the salt bridge between Aps251 on I-
helix and Lys224 on G-helix, allowing the G-helix to move away from I-helix and 
conferring a higher degree of flexibility to this element. This subtle structural change 
is accompanied by long-range structural rearrangements of the active site with the 
rotation of Phe87 and a reorganization of catalytically important water molecules. 
Differential scanning calorimetry shows a population destabilized by 2.2°C compared 
to the wild type protein, probably reflecting the increased flexibility of part of the 
protein compared to WT. Moreover, a shift of the heme reduction potential by 50 mV 
toward positive values, a 2-folds higher first electron transfer rate in the absence of 
oxygen and a 4-folds higher NADPH consumption rate in the presence of oxygen as 
the only electron acceptors, when compared to wild type protein.  
The data demonstrate that a single mutation far away from the active site is able to 
trigger an increase in protein flexibility in a key region of the substrate access 
channel, shifting the conformational equilibrium toward the closed form of the protein 
that is ready to accept electrons and enter the P450 catalytic cycle as soon as a 
substrate is accepted.   
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Cytochrome P450 enzymes are heme-thiolate monoxygenases interesting for 
biocatalytic purposes for their ability of C-H bond functionalization [1]. They have a 
large potential in fields such as drug discovery, fine chemicals synthesis, 
bioremediation, and biotechnology. In particular, those from human liver are 
responsible for Phase I metabolism of drugs, that are converted in one or more 
metabolites. The toxicity and biological activity of such metabolites have to be fully 
characterised during the development of new drugs as they can cause adverse 
reactions in the human body [2]. It is necessary therefore to synthesize preparative 
amounts of these compounds to assess their toxicity, a process that is difficult to 
achieve by classical synthetic methods. The direct use of human cytochrome P450 is 
limited by the need of a redox partner and the poor stability and activity. However, 
bacterial counterparts such as cytochrome P450 BM3 (CYP102A1) from Bacillus 
megaterium, can be directly used [3] or engineered to metabolise drugs and to 
produce the same metabolites as the human enzymes [4-14]. This protein is a self-
sufficient fatty acids monoxygenase containing a NADPH-dependent reductase 
(BMR) and a P450 catalytic domain (BMP) fused in a single polypeptidic chain 
[15,16]. The high catalytic efficiency makes it an excellent template for protein 
engineering aimed at improving substrate versatility and catalytic activity towards 
drugs for the generation of metabolites [14,17-20]. 
Random mutagenesis is a potentially successful approach to introduce new functions 
in enzymes for biocatalytic purposes. However, only the structural characterization of 
the improved variants can elucidate the effect of the randomly introduced mutations 
on protein structure and function, offering the basis for understanding how and why 
an enzyme has evolved to recognize and turn over new molecules. Here, we report 
the crystal structure of the heme domain of the double mutant D251G/Q307H of 
cytochrome P450 BM3, named A2, previously generated and characterized from a 
catalytic point of view for its ability to generate metabolites of diclofenac, ibuprofen 
and tolbutamide [9]. The information from the crystal structure of the mutant also in 
complex with the substrate N-palmytoilglycine together with the comparison with the 
available structures of the wild type enzyme [21,22] were then used for a more 
detailed and comparative functional characterization, giving the rational basis to 
understand why the A2 mutant has evolved toward the recognition and the turnover 
of new substrates due to two mutations far from its active site. 
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Experimental section 
Materials 
All chemicals used for protein expression, purification, characterization and 
crystallization were purchased from Sigma-Aldrich and were analytical grade. 
Restriction enzymes were purchased from New England Biolabs.  
Generation of the heme domain (BMP) of the mutant A2 –The fragment of the gene 
encoding for the heme domain of cytochrome P450 BM3 A2 was extracted by 
digestion with specific restriction enzymes (BamHI and MscI) and ligated into a pT7 
expression vector. The correct insertion of the fragment containing the mutations was 
verified by DNA sequencing. 
Protein expression, purification and quantification – Expression was carried out in 
E.coli BL21 (DE3) cells in Luria-Bertani (LB) medium containing 100 µg mL-1 of 
ampicillin. Cells were grown until the OD600 was 0.7 in 500 mL flask containing 100 
mL of LB medium. Then, the culture was diluted again 1:100 transferring 10 mL of 
the cells grown up to OD600 value of 0.7 into 2 L flasks containing 1 L of medium. 
Once reached an OD600 value of 0.7, protein expression was induced by adding 1 
mM IPTG. The expression was carried out for 19h at 28 °C, 180 rpm shaking. 
Following cell growth, bacterial cells were recovered by centrifugation at 4 °C and 
resuspended in Buffer A (30 mM KPi pH 7.4, 2 mM DTT, 0.1 mM EDTA) containing 
0.1 mM phenyl methyl sulfonyl fluoride (PMSF) and 0.2 mg mL-1 lysozyme. Cells 
were lysed by sonication and the soluble fraction was separated form cell debris by 
centrifugation at 40000 rpm for 25’ at 4 °C. Purification was carried out with some 
modifications as described before [23]. Briefly, a double step anion-exchange 
chromatography using a diethylaminoethyl (DEAE-Sepharose Fast-Flow, GE 
healthcare) and a Q-Sepharose columns (Q-Sepharose Fast Flow, GE Healthcare). 
The fractions containing A2 mutant were pooled and loaded into a 150 mL DEAE 
column and eluted using a 50-250 mM NaCl gradient (500 mL). The protein was then 
exchanged into Buffer A using an Amicon centrifugal filter (Millipore, 30 KDa cut-off) 
in order to remove salt excess and loaded into a Q-Sepharose chromatography 
column (70 mL). The protein was eluted as reported previously for the DEAE and the 
buffer containing NaCl was exchanged with storage buffer 100 mM KPi pH 8.0. The 
fractions containing A2 mutant were analysed for purity by SDS-PAGE gel and 
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pooled according to the purity ratio (A418/A280 = 1.3). A CO-binding assay was 
performed on the purified P450 BM3 WT and A2 proteins in order to estimate their 
concentration in a UV-Vis spectrophotometer (Agilent Technologies) using a 1 cm 
pathlength quartz cuvette, according to the method described by Omura and Sato 
[24]. The protein concentration used to perform the assay was 1 µM. After the 
formation of the Fe(II)CO complex at 450 nm by bubbling CO to the sodium 
dithionite-reduced protein, the extinction coefficient of 91000 M-1 cm-1 was used to 
estimate protein concentration using as absorbance value the ΔAbs450-490. 
Crystallization and determination of protein structures – Crystallization was achieved 
by vapor diffusion method in 24-well sitting drop plates at 4 °C. Using a 
protein:reservoir ratio of 1:1, P450 BMP A2 (20 mg mL-1) was mixed with 
crystallization cocktails containing 14% PEG 3350, 100 mM cacodylic acid in a pH 
range from 5.5 to 6.8 and MgCl2 from 100 to 160 mM. For the N-palmitoylglycine 
(NPG) bound form, the protein was saturated with the ligand and co-crystallized. 
NPG was titrated into BMP sample until full shift to 398 nm was observed. The 
protein was immediately concentrated by ultrafiltration in the presence of saturating 
ligand and used for crystallization purposes. Red crystals were obtained after 3-4 
weeks and were flash-frozen in liquid nitrogen using 10% w/v PEG200 as a 
cryoprotectant. X-ray diffraction data were collected on the ID29 at the European 
Synchrotron Research Facility (Grenoble, France) [25] and on the BL13-XALOC 
beamline at ALBA synchrotron (Cerdanyola del Vallès, Spain) [26]. Data were 
processed using XDS [27] and scaled using AIMLESS [28]. The structure was solved 
by molecular replacement using Molrep [29] from the CCP4 suite [30] and the 
coordinates of the heme domain of P450 BM3 structure (PDB 1JPZ) [22]. The 
models were adjusted using Coot [31] and refined using Refmac5 [32] and PHENIX 
[33]. Coordinates and structure factors have been deposited in the Protein Data 
Bamk (PDB) with accession code 5DYP and 5DYZ. 
Fatty acids binding and NADPH consumption studies – Dissociation constants (KD) 
for binding of the substrate N-palmitoylglycine (NPG) were determined by UV-Vis 
spectrophotometer (Agilent Technologies) in a 1 cm path length quartz cuvette by 
following the typical low-to-high-spin transitions. The reaction mixture contains 1 µM 
of enzyme and substrate in a concentration range from 0.05 to 15 µM. Each 
spectrum was recorded after 3 minutes of equilibration upon each substrate addition 
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at 25°C in a 100 mM KPi pH 8.0 buffer. Difference spectra were generated by 
subtraction of the spectrum for ligand-free protein from spectra recorded after each 
addition of NPG. KD values were determined by plotting the maximal absorbance 
changes calculated from each difference spectrum as a function of substrate 
concentration and by fitting the data using Sigma Plot 12.0.  
Steady-state kinetics of NADPH consumption for P450 BM3 WT and A2 mutant were 
measured by a Agilent 8453 UV-vis spectrophotometer by monitoring the NADPH 
oxidation at 340 nm and using an extinction coefficient at 340 nm of 6,220 M-1 cm-1. 
Reactions were performed in 100 mM KPi pH 8.0 buffer at 25 °C using a protein 
concentration of 0.5 µM, 150 µM NADPH and, when present, saturating amounts of 
the substrate. Each reaction was initiated by the addition of NADPH to the protein 
and performed in triplicate. The rate of NADPH consumption was calculated in the 
first linear part of the reaction.    
 
Stopped-flow experiments – Stopped-flow kinetic experiment were performed on 
cytochrome P450 BM3 WT and A2 mutant in the absence and in the presence of the 
substrate NPG in order to determine the rate constant for the formation of the 
FeII(CO) complex which is strictly dependent on the rate of electron transfer from 
NADPH to heme through the reductase domain (BMR). Experiments were performed 
at 25 °C in 100 mM KPi pH 8.0 buffer using an Hi-Tech Scientific SF-61 stopped-flow 
system in a sealed glove box with O2 concentration < 10 ppm. Prior to analysis, all 
buffers and the solution used were saturated with carbon monoxide (CO) by bubbling 
with the gas for at least 5 minutes. The enzyme (10 µM) present in the first syringe 
was mixed with NADPH (200 µM) in a second syringe in a 1:1 ratio. For the substrate 
bound form, P450 BM3 WT and A2 mutant were saturated with the ligand NPG (15 
µM) prior to be analysed. Absorption changes at 450 nm (reflecting formation of the 
FeII(CO) adduct) were monitored for 5 s after stopped-flow mixing. Each reaction was 
performed at least in quadruplicate. Data were fitted using Kinetic Studio data 
analysis software. 
Redox potentiometry –  Spectroelectrochemical experiment were carried out at 25 °C 
in a quartz cuvette placed in a cuvette holder adaptor connected by a fiber optic 
cable to a spectrophotometer that recorded the spectra and simultaneously to a 
potentiostat to measure the redox potential. The measurements were performed in 
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anaerobiosis (O2 concentration was less than 10 ppm) by a continuous flow of 
nitrogen gas within the otherwise sealed glove box using an Ag/AgCl reference 
electrode and a laminar gold working electrode. Sodium dithionite was used as the 
reducing agent for the titrations, aliquots of 1.25 µM were added each time to the 
protein solution until complete reduction was observed. Protein and sodium dithionite 
solutions were prepared in 100 mM KPi pH 8.0 buffer. After each addition of sodium 
dithionite the sample was stirred and the system was allowed to equilibrate for at 
least 15 minutes. After equilibration at each potential the optical spectrum was 
recorded. Redox mediators (methylene blue, O-safranine, phenazine methosulfate, 
anthraquinone-2,6-disulfonic acid, benzyl viologen and methyl viologen) were also 
added to the sample to facilitate electrochemical communication between the protein 
and the electrode. The concentration of the mediators was 30 times less compared to 
that of the protein, 3 µM protein versus 0.1 µM mediator. All the redox mediators 
(except benzyl viologen and methyl viologen that were diluted in water) were 
prepared in methanol to a final concentration of 5 mM. Then a 0.05 mM solution of 
each mediator was prepared using 100 mM KPi pH 8.0. Finally, putting all the 
mediators together we prepared the mix used in the experiment. Reduction 
potentials, expressed relative to the standard hydrogen reference electrode (NHE), 
were obtained from the experimental data points fitted to the theoretical Nernst 
equation by fitting the percentage of oxidized fraction of the protein calculated using 
the absorbance values at 419 nm for the ligand-free and 398 nm for the substrate-
bound protein versus the potential. Each plot is the result of at least three 
experiments.  
Differential scanning calorimetry (DSC) – DSC was carried out on a Microcal VP-
DSC instrument. Data analysis was performed using Microcal Origin software. The 
parameters used were as follows: 25–105 °C temperature gradient, 90 °C/h scan 
rate, 10 minutes prescan thermostat. Background scans were carried out with 
degassed 100 mM KPi pH 8.0 buffer and saturated with NPG for the substrate-bound 
samples. All samples were run using 10 µM proteins and saturating amounts of the 
substrate, when present.  
 
Results and discussion  
Crystal structures of the heme domain of A2 
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The crystal structure of the heme domain of P450 BM3 A2 in the substrate-free and –
bound forms was solved at 2.4 and 1.97 Å resolution, respectively. Data collection 
and refinement statistics are reported in Table 1.  
Figure 1A shows a superimposition of the crystal structure of P450 BMP A2 and the 
substrate-free structure of the wild type protein (PDB ID 1 BU7) [21]. The overall 
RMSD is 0.625-0.721 Å, depending on the monomer taken into account and 
superimposed, and the most significant changes are seen in F- and G- helices, that 
are part of the substrate access channel in P450 BM3 [21]. In line with previously 
published crystal structures of different cytochromes P450, the F-G loop and part of 
the G-helix are unresolved in A2 mutant or present the highest B factors, suggesting 
a high degree of disorder that has been attributed to a high level of flexibility of this 
part of the P450 fold [34-36]. The high degree of flexibility in A2 mutant is the result 
of the replacement of Asp251 with a glycine, that significantly affects the structure 
since the salt bridge involving Asp251 and Lys224 is broken, resulting in re-
positioning of helix G (Figure 2A). However, the movement of helix G is restricted by 
the new conformation adopted by Arg255 side-chain that allows the conservation of a 
salt bridge with Asp217 found also in the WT protein (Figure 2A). This side chain 
elongation of Arg255 was also found in another mutant of P450 BM3, named KT2, 
carrying 5 mutations and with enhanced activity compared to the WT protein [37,38]. 
The second mutation of A2, Gln307His, is located on the protein surface and involves 
the last residue of helix J’. This mutation removes the hydrogen bond present 
between Gln307 and Asp300 and introduces a new hydrogen bond between Gln307 
and Ser304 (Figure 2B). As a result, the local structure is not significantly altered by 
this mutation compared to the wild type protein. 
When the BMP A2 mutant structure is superimposed to that of substrate-bound BMP 
wild type, the RMSD decreases to 0.559-0.619 and only minor differences in helix G 
and some external loops are present (Figure 1B). Thus, the mutations introduced in 
A2 mutant cause a conformational change similar to that induced by substrate 
binding in the wild type protein. Interestingly, this mutation-induced conformational 
change was also found for other mutants of cytochrome P450 BM3 but it is was 
mainly due to active site mutations, or by a combination of five mutations [10,38]. 
Here, the same conformational effect is achieved by only one mutation breaking a 
key salt bridge on the protein surface. This conformational change is significant since 
it has a long-range effect on the structure of the active site of the protein. In fact, a 
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close look in the catalytic pocket shows some subtle changes that are usually 
triggered by substrate binding. First, the water molecule present as sixth ligand of the 
heme iron atom is in an off-axial position by 12°C compared to BMP WT structure 
and at a distance of 2.8 Å (Figure 3A). This is consistent with the unstable 
predominantly low spin state observed in the variant that is however very sensitive to 
slight changes of ionic strength and pH. Secondly, the residue Phe87, a residue 
involved in a rotational movement when the substrate is bound, is already almost 
completely rotated in the substrate-free form of A2 mutant, as in the substrate-bound 
WT structure (Figure 3A). Since it has been proposed that the spin equilibrium in 
P450 BM3 is affected by Phe87, this is an important change since it facilitates both 
the access of substrates to the active site of the protein and the water displacement 
[39,40]. Moreover, some residue side chains such as Phe261 and His266 that 
undergo major changes upon substrate binding, are already in the substrate-bound 
conformation. Finally, the so-called kink region of helix I is also more similar to the 
substrate-bound WT. In fact, the water molecule present in the groove formed by the 
disruption of the intrahelical hydrogen bond pattern in the substrate-free WT enzyme 
is missing in A2 mutant (Wat2 in Figure 3A). As a result, the kink is less pronounced 
compared to the substrate-bound WT enzyme and this is due to the disruption of the 
hydrogen bonds between Leu262CO-His266NH and Ala264CO-Thr268NH (Figure 
3B). Moreover a water molecule, corresponding to Wat501 in the structure of BMP 
WT in complex with N-palmitoylglycine (1JPZ), is present in a similar position and 
forms hydrogen bonds with Ala264, Thr268 and Thr269 (Wat3 in Figure 3A). Ala264 
also forms a hydrogen bond with the axial water ligated to the heme iron as in the 
WT enzyme (Figure 3B). 
The crystal structure of A2 mutant in complex with N-palmytoilglycine (NPG), a 
known substrate of P450 BM3 [22], was also solved and the electron density of the 
substrate was visible in one of the monomer (Figure 4A). The overall structure is very 
similar to that of substrate-free A2 mutant (RMSD 0.583 Å). The substrate NPG 
resulted in a slightly different position in A2 mutant compared to the WT enzyme [22] 
and bound to Tyr51, Gln73 and Ala74 through hydrogen bonds (Figure 4A). In our 
structure, Arg47 is not involved in NPG binding whereas a previously published 
crystal structure BMP WT in complex with NPG shows that this residue is involved in 
binding  [42]. 
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The axial water ligand is now 3 Å far away from the heme iron in an off-axial location 
increased by 14° and the water molecule in the helix I groove overlays with Wat501 
in BMP WT-NPG complex structure (PDB 1JPZ) and with the water molecule found 
in substrate-free A2 mutant (Figure 4B). Thus, upon substrate binding, even if with 
differences compared to the WT enzyme, there is a relocation of the water molecules 
responsible for the spin shift and thought to be important for oxygen binding and 
catalysis [22]. 
Since the mutant A2 has been shown to have new catalytic abilities toward 
diclofenac, ibuprofen and tolbutamide [9], co-crystallization experiments were also 
performed by complexing the enzyme with the three drugs at saturating 
concentrations before crystallization and monitoring the spin shift associated to the 
drug binding. For the A2-diclofenac complex, diffraction data were collected at 2.0 Å 
resolution and the structure solved. A positive density in the active site and in 
proximity of Arg47 in the difference electron density map was observed but fitting a 
diclofenac molecule resulted in an increase in the Rfree factor during refinement even 
if alternative conformations of the drug were used to fit the electron density. This 
result suggests that the drug enters the active site of the protein but it is highly mobile, 
most probably due to the lack of stable interactions with the residues of the substrate 
binding site. Indeed, these residues are not changed in A2 mutant compared to the 
wild type protein that is not able to bind and turn over the drug and, in fact, the KD 
values measured for the substrate NPG is similar for WT and A2 mutant (0.73 ± 0.07 
and 0.54 ± 0.07 µM, respectively).  
The structural data, taken together, suggest that the mutation Asp251Gly introduces 
a higher degree of flexibility of part of the access channel compared to WT, that can 
increase the probability to introduce new molecules to the active site of the protein. 
The mutation is responsible for an overall open-to-close conformational transition 
with a long-range effect on the active site, where the rotation of Phe87 facilitates the 
entrance of substrates close to the heme iron. Moreover, a rearrangement of the 
active site water molecules, similar to the one induced by substrate binding in the WT 
protein, is seen in A2 mutant. 
 
 
Differential scanning calorimetry (DSC). 
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In order to investigate the role of the conformational change of the protein in relation 
to its stability and flexibility, differential scanning calorimetry experiments were 
performed fro BMP WT and A2 in the absence and presence of the NPG substrate. 
The results are shown in Figure 5 and the melting temperatures (Tm) calculated are 
reported in Table 2.  
The DSC profile of the WT protein in the absence of substrate shows a wide peak 
that can be deconvoluted into two components with Tm1 of 55.8  and Tm2 of 61.4°C. 
Upon NPG binding, the two transitions become better resolved with a Tm1 of 61.4 and 
a Tm2 of 66.5°C. The presence of two transitions could be ascribed to the presence in 
BMP of two sub-domains [43] while the increase of the Tm values observed upon 
substrate addition is consistent with the additional interactions between the protein 
and the substrate leading to a conformational change known to decrease the 
flexibility of the protein [21,22]. 
Based on the knowledge of the BMP A2 structure described in the previous section, it 
might be expected that the DSC profile of A2 mutant is similar to that of the 
substrate-bound WT. Figure 5C indeed shows that the substrate-free A2 mutant 
displays two transitions even better resolved than those of the substrate-bound WT. 
However, the Tm1 and Tm2 values are found to be 53.6 and 61.7°C respectively, that 
are lower than the corresponding values found for substrate-bound WT. This can be 
ascribed to the absence of the stabilizing interactions of A2 mutant with the substrate. 
Moreover, the comparison of Tm1 and Tm2 values of the substrate-free proteins, show a 
lower Tm1 value for the substrate-free A2 mutant. In line with the structure of BMP A2, 
this suggests a higher degree of flexibility in this protein as indicated by the presence 
of disordered regions. The effect of substrate addition to A2 mutant on the DSC 
profile is shown in Figure 5D. The apparent less resolved peak profile is due to the 
presence of a new component (Tm3) at 66.0°C, while Tm1 and Tm2 remain comparable 
to that found in the substrate-free A2. This is consistent with a more rigid protein 
conformation imposed by the presence of the substrate as also observed for WT. 
However, in substrate-bound A2, the presence of a flexible component represented 
by Tm1 still persists. 
Our data are also in line with the results from the crystal structures of other mutants 
of cytochrome P40 BM3 with catalytic new abilities compared to WT [10,38] where 
the effect of the mutations is to promote the conformational change and the structural 
rearrangements that bring the protein to adopt a conformation similar to the 
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substrate-bound form of the WT protein. However, for those variants the 
conformational rearrangements are induced either by single and double active site 
mutations or by a combination of mutations far from the active site [10,38]. For some 
of them, the catalytic improvements of the variants were explained in terms of a 
decrease in the free energy barrier necessary to the protein for the transition from the 
substrate-free to the –bound conformations [10,38]. In fact, DSC experiments 
showed that the addition of substrate induces only a small thermal stabilization in the 
mutants (already in the closed conformation) compared to the WT protein, where a 
stabilization by 5-6°C is achieved by substrate addition upon the change from the 
open to the closed conformation [10]. Our data data suggest that the removal of a 
salt bridge in A2 mutant has an effect on the stability of the protein and, from the 
crystallographic data, this can be explained with the increase in the conformational 
flexibility of the G-helix found in the mutant A2.  
 
Impact of structure on P450 BMP A2 functional properties 
The structure of the A2 mutant shows a rearrangement of the water molecules within 
the active site cavity (Figure 3). As this could affect the redox properties of the metal 
center, spectroelectrochemistry was used to determine the reduction potential of the 
mutant. The results are summarized in Table 3. Though both WT and A2 show a shift 
of the reduction potential (Em) toward positive values upon substrate binding, the Em 
value of substrate-free A2 is within the error the same as that of the substrate bound 
WT. This can be explained by the analysis of the x-ray structure of substrate-free A2 
where the position of the water molecule is close to that found in the substrate-bound 
WT. Addition of the substrate leads to a 42 mV shift toward positive values for the 
WT, while in the A2 mutant this leads to only a +26 mV shift. The lower positive shift 
in reduction potential observed for the mutant A2 is also coherent with the different 
position of the water molecules.  
All together these results can be explained by the partially off-axial position of the 
water molecule found in A2, as well as the pattern of hydrogen bond involving the 
residues of the helix I and the water molecules (Figure 3B) and, more in general, the 
changed structural environment compared to the WT protein. Moreover, the 
reduction potential of the mutant A2 moves toward even more positive values when 
the substrate NPG is added, consistent with the movement of the water molecule to a 
more distant and off-axial position (Figure 4B). 
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Since the substrate-induced shift of the reduction potential toward positive values 
triggers the first electron transfer in the catalytic cycle of cytochrome P450, stopped 
flow measurements were used to follow the first electron transfer kinetics from 
NADPH to the heme domain of P450 BM3 WT and A2. This is possible because the 
reduced form of the heme iron atom is able to bind CO and form a complex with a 
typical absorption band at 450 nm. 
Figure 7 shows the results obtained from the two proteins in the absence and 
presence of the substrate NPG. The increase at 450 nm was better fitted to a bi-
exponential as a function of time that led to the rate constants (k1 and k2) reported in 
Table 3. This behavior was previously observed for BMP WT and other mutants and 
can be attributed to the presence of a spin equilibrium leading to two populations of 
protein in high and low spin, respectively (38). The first rate for the mutant A2 is 2-
folds higher compared to the WT enzyme. When the substrate NPG is added, as 
expected, the electron transfer rate increases by 2-folds for the WT protein and this is 
consistent with the shift of the reduction potential toward positive values previously 
observed. For A2, the value remains unchanged upon substrate addition as the 
reduction potential is similar for the substrate-free and –bound proteins, suggesting 
that the substrate-free conformation of the enzyme is already “prone” to accept the 
electrons. 
The results suggest that the conformational change observed in BMP A2 induce a 
shift of the reduction potential toward positive values favoring the first electron 
transfer. This means that, when a substrate is accepted in the active site, the mutant 
is more “ready” than the WT protein to go though the catalytic cycle. This is 
confirmed by the results shown in Table 3, where the NADPH basal consumption of 
P450 BM3 WT and A2 in the presence of oxygen measured at 340 nm is reported. 
As it can be seen, the rates of NADPH consumption is 4-folds higher in P450 BM3 
A2 compared to the WT protein, suggesting that electrons are flowing through the 
system to oxygen faster than in WT, even if a substrate is not present. This last 
feature is usually associated to the uncoupling of reducing equivalents for reactive 
oxygen species production rather than for product formation found in cytochromes 
P450 [1,44]. This may be the reason why the turnover rate for drugs in A2 mutant is 
much lower than the NADPH consumption rate, suggesting a high level of uncoupling 
[9]. Furthermore, these data confirm that a slower electron transfer is usually 
associated to a higher level of coupling [45-47]. 
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Conclusions 
In conclusion, the crystal structure of P450 BMP A2 together with the functional data 
highlights the importance for catalysis of mutations far from the active site but having 
long-range effects on it. From a structural point of view, the ability to recognize new 
substrates can be achieved by a specific mutation in a plastic region of substrate 
access channel that becomes more flexible and facilitates the transition from the 
open to the closed conformation of the enzyme as well as substrate entrance. The 
conformational change is responsible for a series of events in the active site that 
trigger the shift of the reduction potential toward positive values that facilitates the 
electron flow through the system compared to the WT protein.   
The benefit of the mutations can be seen in terms of a higher degree of flexibility of 
the mutant compared to WT that facilitates the access of substrates also due to the 
reorientation of specific side chains such as Phe87. Once the substrates are 
accepted, the protein is in a catalytically ready conformation, where the structural 
rearrangements are key to trigger the first events of the P450 catalytic cycle. Thus, 
the typical cascade of events usually associated with substrate binding (i.e. 
conformational change, water displacement, shift of the reduction potential and first 
electron transfer) that represents a fine control mechanism in P450 BM3 WT is at 
least partially lost in mutant A2 that behaves similar to a “loaded gun” catalyst. 
Indeed, as expected from a first round of random mutagenesis, the mutations 
produced the so-called “generalist” [48] that can be used for other rounds of directed 
evolution to generate variants more specific toward the substrates of interest.  
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Tables 
 
Table 1. X-ray data collection and refinement statistics for variant A2 
 BMP A2  
PDB ID 5DYP 
BMP A2 + NPG  
PDB ID 5DYZ 
 
Data collection 
 
Space group P212121 P212121 
Cell dimensions a/b/c/Å 
61.13 
118.45 
146.95 
61.21 
115.71 
143.28 
Wavelength (Å) 0.98 0.98 
Resolution (Å) 2.40 1.97 
Average I/σ(I) 13.2 (2.6)a 12.0 (2.1) a 
Completeness (%) 98.6 (99.6)  99.6 (94.7) 
Redundancy 5.5 (5.5) 6.5 (6) 
Rmerge 0.07 (0.572) 0.09 (0.864) 
 
Refinement 
 
Average B-factor (Å2) 73.0 40.0 
R work/R free (%) 22.0/25.7 18.6/22.4 
r.m.s.d. bond lengths (Å) 0.006 0.010 
r.m.s.d. bond angles (°) 1.228 1.309 
a Values in parentheses are for the highest-resolution shell.   
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Table 2. DSC parameters for BMP WT and BMP A2 in the substrate-free and NPG-
bound forms.  
 
 
 
 
 
 
 
Table 3. Reduction potentials, first electron transfer rates in the absence of oxygen 
and presence of CO and NADPH consumption rates in the presence of oxygen for 
P450 BM3 WT and A2. 
 
Sample 
Em (vs NHE) / mV  
(only heme domain) 
FeII(CO) complex 
formation rates (s-1) 
NADPH consumption rate (mol 
NADPH/mol protein/min-1) 
 
BM3 WT -387 ± 2 
k1 = 11.8 ± 0.8 
     k2 = 1.0 ± 0.2 
32.3 ± 2.0 
BM3 A2 -342 ± 3 
k1 = 19.8 ± 0.9 
     k2 =1.3 ± 0.1 
129.0 ± 1 
BM3 WT + NPG -345 ± 5 
k1 = 23.4 ± 1.2 
      k2 = 1.4 ± 0.1 
451.6 ± 3.0 
BM3 A2 + NPG -326 ± 6 
k1 = 17.6 ± 1.5 
      k2 = 1.2 ± 0.1 
645.2 ± 3.0 
 
 
 
 
  
Sample Tm1 ΔH1 (kcal mol-1) Tm2 ΔH2 (kcal mol-1) Tm3 ΔH3 (kcla mol-1) 
BMP WT 55.8 ± 0.3 8.269E4 ± 5.25E3 61.4 ± 0.1 7.388E4 ± 5.09E3   
BMP WT 
+ NPG 61.4 ± 0.1 1.684E5 ± 4.53E3 
66.5 ± 0.1 1.300E5 ± 4.32E3   
BMP A2 53.6 ± 0.1 1.085E5 ± 578 61.7 ± 0.1 6.514E4 ± 554   
BMP A2 
+ NPG 
53.0 ± 0.2 9.206E4 ± 4.58E3 60.0 ± 0.1 1.736E5 ± 7.38E3 66.0 ± 0.1 2.803E4 ± 3.28E3 
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Figure legends. 
Figure 1. Overall crystal structure superimposition of the heme domain (BMP) of 
P450 BM3 A2 (brown) with A) substrate-free BMP WT (cyan, PDB ID 1BU7) [21] and 
B) NPG-bound BMP WT (magenta, PDB ID 1JPZ) [22]. 
Figure 2. Structural overlay of BMP WT and A2 in the regions where the mutation of 
A2 are located. A) Asp251 is part of the I-helix in BMP WT (cyan) and forms a salt 
bridge with Lys 224 of G-helix. In A2, the salt bridge cannot be formed because of 
the Asp251Gly mutation and, as a result, the G-helix moves far away from I-helix. 
This movement is however restricted by the presence both in WT and A2 of the salt 
bridge between Asp217 and Arg255 that is in a more extended conformation in A2. 
B) Local effect of the Gln307His mutation. Gln307 forms a hydrogen bond with 
Asp300 in the WT (cyan). This hydrogen bond is not more present in A2. A new 
hydrogen bond is formed between His307 and Ser403 (brown). The local structure is 
not perturbed by this mutation. 
Figure 3. Active site of BMP A2. A) Structural overlays showing the rotation of Phe87 
in BMP WT (cyan) as a consequence of substrate binding (magenta).  In the active 
site of BMP A2 (tan), Phe87 is almost completely rotated to the substrate-bound 
position and this movement probably favors substrate access to the active site. In A2 
(brown), the I-helix distortion do to the presence of a water molecule that disrupt the 
regular intra-helical H-bond pattern (Wat2, cyan), is not present as in the substrate-
bound (magenta) WT protein. A water molecule (Wat3) is instead located where it is 
in the substrate-bound structure (magenta). B) Hydrogen bond pattern involving the 
water molecules in A2. The off-axial water molecule is hydrogen bonded to the CO 
group of Ala264 that is hydrogen bonded to the water molecule that interrupts the 
intrahelical hydrogen bond pattern. 
Figure 4. Structure of BMP A2 in complex with the substrate NPG. A) Active site of 
the protein showing an unbiased difference electron density (contoured at 2.5 σ) for 
the bound N-palmitoylglycine (NPG), and the residues involved in hydrogen bonds 
with the substrate. B) Structural overlay between substrate-free (brown) and –bound 
(green) BMP A2, showing the movement of the water molecule Wat1, the rotation of 
Phe87 and the fixed position of Wat3. 
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Figure 5. Differential scanning calorimetry (DSC) profiles for A) BMP WT, B) BMP 
WT in complex with NPG, C) BMP A2 and D) BMP A2 in complex with NPG.  
Figure 6. Spectroelectrochemical titrations of the heme domain of P450 BM3 A2 in A) 
substrate-free and B) NPG-bound forms. The black traces represent the initial fully-
oxidised spectra whereas the red traces represent the fully-reduced final spectra. 
The insets show the plot of the percentage of oxidized fraction, calculated from the 
absorbance changes at A) 419 and B) 398 nm as a function of the potential 
measured and the fitting to the Nernst equation with the number of electrons fixed at 
1. 
Figure 7. Stopped flow kinetics of CO binding for A) BMP WT, B) BMP WT in 
complex with NPG, C) BMP A2 and D) BMP A2 in complex with NPG. In all cases, 
the black trace represents the initial spectrum whereas the red trace represents the 
spectrum after 1 second. The insets represent the plots of the absorbance at 450 nm 
as a function of time and fitting to double exponential curves. 
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